CXCL10 and asthma: In this relatively small cohort of patients with severe asthma receiving mepolizumab or omalizumab, baseline plasma IL-13 levels were differentially expressed and higher in patients who subsequently had a clinical response to mepolizumab, while plasma CXCL10 levels were higher in responders to omalizumab.